내용 바로 가기

종양학과

혈소판감소증(Thrombocytopenia) 관리

Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (새로운 창 열기)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Source‎: Br J Haematol 2013;161(5):738-40.

Indexed‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (새로운 창 열기)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (새로운 창 열기)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Source‎: Haematologica 2021;106(4):1148-57.

Indexed‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (새로운 창 열기)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (새로운 창 열기)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Source‎: Cancer 2008;113(6):1338-43.

Indexed‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (새로운 창 열기)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (새로운 창 열기)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Source‎: Transfusion 2012;52(4):739-41.

Indexed‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (새로운 창 열기)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (새로운 창 열기)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Source‎: BMC Cancer 2013;13:121.

Indexed‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (새로운 창 열기)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (새로운 창 열기)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Source‎: Pathol Oncol Res 2011;17(1):141-3.

Indexed‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (새로운 창 열기)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (새로운 창 열기)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Source‎: J Neurooncol 2012;106(2):427-9.

Indexed‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (새로운 창 열기)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (새로운 창 열기)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Source‎: Platelets. 2022 3;33(7):1024-1030.

Indexed‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (새로운 창 열기)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (새로운 창 열기)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Source‎: Cancer 2014;120(12):1838-46.

Indexed‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (새로운 창 열기)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (새로운 창 열기)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Source‎: Leuk Lymphoma 2013;54(2):321-8.

Indexed‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (새로운 창 열기)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (새로운 창 열기)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Source‎: Platelets 2012;23(6):423-9.

Indexed‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (새로운 창 열기)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (새로운 창 열기)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Source‎: Ann Hematol 2015;94(1):117-28.

Indexed‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (새로운 창 열기)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (새로운 창 열기)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Source‎: J Hematol Oncol 2015;8:37.

Indexed‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (새로운 창 열기)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (새로운 창 열기)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Source‎: J Clin Oncol 2010;28(3):437-44.

Indexed‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (새로운 창 열기)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (새로운 창 열기)

Miao J, Leblebjian H, Scullion B, Parnes A

Source‎: Am J Hematol 2018;93(4):E86-E88.

Indexed‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (새로운 창 열기)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (새로운 창 열기)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Source‎: Support Care Cancer 2014;22(5):1217-22.

Indexed‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (새로운 창 열기)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (새로운 창 열기)

Pathak S, Roth M, Verma A, Steidl U.

Source‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indexed‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (새로운 창 열기)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (새로운 창 열기)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Source‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexed‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (새로운 창 열기)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (새로운 창 열기)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Source‎: Lancet Haematol 2015;2(10):e417-26.

Indexed‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (새로운 창 열기)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (새로운 창 열기)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Source‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indexed‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (새로운 창 열기)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (새로운 창 열기)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Source‎: Blood 2010;116(12):2127-33.

Indexed‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (새로운 창 열기)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (새로운 창 열기)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Source‎: Blood 2012;120(2):386-94.

Indexed‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (새로운 창 열기)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (새로운 창 열기)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Source‎: Cancer 2011;117(5):992-1000.

Indexed‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (새로운 창 열기)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (새로운 창 열기)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Source‎: J Clin Oncol 2019;37(31):2892-8.

Indexed‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (새로운 창 열기)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (새로운 창 열기)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Source‎: Blood 2000;95(9):2983-9.

Indexed‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (새로운 창 열기)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (새로운 창 열기)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Source‎: Eur J Haematol 2014;93(5):439-45.

Indexed‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (새로운 창 열기)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (새로운 창 열기)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Source‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indexed‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (새로운 창 열기)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (새로운 창 열기)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Source‎: Ann Oncol 2005;16(1):139-45.

Indexed‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (새로운 창 열기)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (새로운 창 열기)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Source‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indexed‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (새로운 창 열기)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (새로운 창 열기)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Source‎: Blood 2009;114(18):3899-908.

Indexed‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (새로운 창 열기)